Germline mutation in BRAF codon 600 is compatible with human development: De novo p.V600G mutation identified in a patient with CFC syndrome

K. J. Champion, C. Bunag, A. L. Estep, J. R. Jones, C. H. Bolt, R. C. Rogers, Katherine A Rauen, D. Everman

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

BRAF, the protein product of BRAF, is a serine/threonine protein kinase and one of the direct downstream effectors of Ras. Somatic mutations in BRAF occur in numerous human cancers, whereas germline BRAF mutations cause cardio-facio-cutaneous (CFC) syndrome. One recurrent somatic mutation, p.V600E, is frequently found in several tumor types, such as melanoma, papillary thyroid carcinoma, colon cancer, and ovarian cancer. However, a germline mutation affecting codon 600 has never been described. Here, we present a patient with CFC syndrome and a de novo germline mutation involving codon 600 of BRAF, thus providing the first evidence that a pathogenic germline mutation involving this critical codon is not only compatible with development but can also cause the CFC phenotype. In vitro functional analysis shows that this mutation, which replaces a valine with a glycine at codon 600 (p.V600G), leads to increased ERK and ELK phosphorylation compared to wild-type BRAF but is less strongly activating than the cancer-associated p.V600E mutation.

Original languageEnglish (US)
Pages (from-to)468-474
Number of pages7
JournalClinical Genetics
Volume79
Issue number5
DOIs
StatePublished - May 2011
Externally publishedYes

Fingerprint

Germ-Line Mutation
Human Development
Codon
Mutation
Neoplasms
Protein-Serine-Threonine Kinases
Valine
Ovarian Neoplasms
Colonic Neoplasms
Glycine
Melanoma
Phosphorylation
Phenotype
Skin
Cardiofaciocutaneous syndrome
Proteins

Keywords

  • BRAF
  • Cardio-facio-cutaneous syndrome
  • Germline
  • P.V600E
  • P.V600G
  • Ras/MAPK pathway
  • RASopathy
  • Signal transduction

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

Germline mutation in BRAF codon 600 is compatible with human development : De novo p.V600G mutation identified in a patient with CFC syndrome. / Champion, K. J.; Bunag, C.; Estep, A. L.; Jones, J. R.; Bolt, C. H.; Rogers, R. C.; Rauen, Katherine A; Everman, D.

In: Clinical Genetics, Vol. 79, No. 5, 05.2011, p. 468-474.

Research output: Contribution to journalArticle

Champion, K. J. ; Bunag, C. ; Estep, A. L. ; Jones, J. R. ; Bolt, C. H. ; Rogers, R. C. ; Rauen, Katherine A ; Everman, D. / Germline mutation in BRAF codon 600 is compatible with human development : De novo p.V600G mutation identified in a patient with CFC syndrome. In: Clinical Genetics. 2011 ; Vol. 79, No. 5. pp. 468-474.
@article{189d5528f5d1484e9cbcf9f16a599381,
title = "Germline mutation in BRAF codon 600 is compatible with human development: De novo p.V600G mutation identified in a patient with CFC syndrome",
abstract = "BRAF, the protein product of BRAF, is a serine/threonine protein kinase and one of the direct downstream effectors of Ras. Somatic mutations in BRAF occur in numerous human cancers, whereas germline BRAF mutations cause cardio-facio-cutaneous (CFC) syndrome. One recurrent somatic mutation, p.V600E, is frequently found in several tumor types, such as melanoma, papillary thyroid carcinoma, colon cancer, and ovarian cancer. However, a germline mutation affecting codon 600 has never been described. Here, we present a patient with CFC syndrome and a de novo germline mutation involving codon 600 of BRAF, thus providing the first evidence that a pathogenic germline mutation involving this critical codon is not only compatible with development but can also cause the CFC phenotype. In vitro functional analysis shows that this mutation, which replaces a valine with a glycine at codon 600 (p.V600G), leads to increased ERK and ELK phosphorylation compared to wild-type BRAF but is less strongly activating than the cancer-associated p.V600E mutation.",
keywords = "BRAF, Cardio-facio-cutaneous syndrome, Germline, P.V600E, P.V600G, Ras/MAPK pathway, RASopathy, Signal transduction",
author = "Champion, {K. J.} and C. Bunag and Estep, {A. L.} and Jones, {J. R.} and Bolt, {C. H.} and Rogers, {R. C.} and Rauen, {Katherine A} and D. Everman",
year = "2011",
month = "5",
doi = "10.1111/j.1399-0004.2010.01495.x",
language = "English (US)",
volume = "79",
pages = "468--474",
journal = "Clinical Genetics",
issn = "0009-9163",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Germline mutation in BRAF codon 600 is compatible with human development

T2 - De novo p.V600G mutation identified in a patient with CFC syndrome

AU - Champion, K. J.

AU - Bunag, C.

AU - Estep, A. L.

AU - Jones, J. R.

AU - Bolt, C. H.

AU - Rogers, R. C.

AU - Rauen, Katherine A

AU - Everman, D.

PY - 2011/5

Y1 - 2011/5

N2 - BRAF, the protein product of BRAF, is a serine/threonine protein kinase and one of the direct downstream effectors of Ras. Somatic mutations in BRAF occur in numerous human cancers, whereas germline BRAF mutations cause cardio-facio-cutaneous (CFC) syndrome. One recurrent somatic mutation, p.V600E, is frequently found in several tumor types, such as melanoma, papillary thyroid carcinoma, colon cancer, and ovarian cancer. However, a germline mutation affecting codon 600 has never been described. Here, we present a patient with CFC syndrome and a de novo germline mutation involving codon 600 of BRAF, thus providing the first evidence that a pathogenic germline mutation involving this critical codon is not only compatible with development but can also cause the CFC phenotype. In vitro functional analysis shows that this mutation, which replaces a valine with a glycine at codon 600 (p.V600G), leads to increased ERK and ELK phosphorylation compared to wild-type BRAF but is less strongly activating than the cancer-associated p.V600E mutation.

AB - BRAF, the protein product of BRAF, is a serine/threonine protein kinase and one of the direct downstream effectors of Ras. Somatic mutations in BRAF occur in numerous human cancers, whereas germline BRAF mutations cause cardio-facio-cutaneous (CFC) syndrome. One recurrent somatic mutation, p.V600E, is frequently found in several tumor types, such as melanoma, papillary thyroid carcinoma, colon cancer, and ovarian cancer. However, a germline mutation affecting codon 600 has never been described. Here, we present a patient with CFC syndrome and a de novo germline mutation involving codon 600 of BRAF, thus providing the first evidence that a pathogenic germline mutation involving this critical codon is not only compatible with development but can also cause the CFC phenotype. In vitro functional analysis shows that this mutation, which replaces a valine with a glycine at codon 600 (p.V600G), leads to increased ERK and ELK phosphorylation compared to wild-type BRAF but is less strongly activating than the cancer-associated p.V600E mutation.

KW - BRAF

KW - Cardio-facio-cutaneous syndrome

KW - Germline

KW - P.V600E

KW - P.V600G

KW - Ras/MAPK pathway

KW - RASopathy

KW - Signal transduction

UR - http://www.scopus.com/inward/record.url?scp=79953738626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953738626&partnerID=8YFLogxK

U2 - 10.1111/j.1399-0004.2010.01495.x

DO - 10.1111/j.1399-0004.2010.01495.x

M3 - Article

C2 - 20735442

AN - SCOPUS:79953738626

VL - 79

SP - 468

EP - 474

JO - Clinical Genetics

JF - Clinical Genetics

SN - 0009-9163

IS - 5

ER -